Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Intervalo de año de publicación
1.
Z Gastroenterol ; 37(6): 513-8, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10427658

RESUMEN

The first component of the classical pathway of the complement system, C1 is regulated by a serum protein, the C1-esterase inhibitor (C1-INH). Deficiency of this protein leads to the release of vasoactive mediators (C2 kinin and bradykinin) that increase vascular permeability and can induce edema formation in subcutaneous and submucosal tissues. The genetic variant of C1-INH deficiency is inherited as an autosomal dominant trait and causes hereditary angioneurotic edema. The acquired form of C1-INH deficiency is characterized by similar manifestations and can occur in association with lymphoproliferative diseases, malignancy, immune disorders, and infections. The authors present a case of acquired C1-INH deficiency in a patient with Helicobacter pylori infection. Complete eradication of this pathogen was followed by the resolution of symptoms and normalization of serum complement levels. It seems therefore probable that in this patient, acquired C1-INH deficiency was related to Helicobacter pylori infection. To our best knowledge, no similar observations have been published so far. Specific immune reactions are important contributing factors in H. pylori. Excessive consumption of complement by antibodies directed against H. pylori is a potential cause of C1-INH deficiency observed in our case.


Asunto(s)
Angioedema/etiología , Proteínas Inactivadoras del Complemento 1/deficiencia , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Adulto , Antibacterianos/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Autoanticuerpos/análisis , Ciprofloxacina/administración & dosificación , Proteínas Inactivadoras del Complemento 1/inmunología , Quimioterapia Combinada , Femenino , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/inmunología , Helicobacter pylori/inmunología , Humanos , Metronidazol/administración & dosificación , Salicilatos/administración & dosificación , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA